Johnson & Johnson logo
Johnson & Johnson JNJ
$ 247.82 -0.26%

Annual report 2025
added 02-11-2026

report update icon

Johnson & Johnson Financial Ratios 2011-2026 | JNJ

Annual Financial Ratios Johnson & Johnson

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

- 26.9 11.5 94.1 30.2 - 26.0 22.4 18.0 18.6 - 17.6 18.3 19.5 12.6

P/S

- 4.3 4.7 21.0 5.4 - 4.8 4.2 4.1 4.1 - 3.9 3.5 2.9 2.7

EPS

11.1 5.8 13.9 1.7 5.6 - 5.7 5.7 0.5 5.6 - 5.8 4.9 3.9 4.8

EV (Enterprise Value)

98 B 463 B 481 B 513 B 542 B - 475 B 418 B 351 B 335 B - 334 B 291 B 230 B 195 B

EBITDA per Share

3.12 3.05 2.95 2.81 2.75 - 9.24 9.47 8.95 8.28 - 8.69 6.97 5.43 7.16

EV/EBITDA

74.7 - 17.1 14.7 13.4 13.1 - 12.4 13.6 13.1 9.1

PEG

- - 74.19 0.02 2.09 -4.52 - 0.99 0.73 -0.72 1.45

P/B

- 5.3 5.9 5.7 7.0 - 6.6 5.7 4.2 4.0 - 4.1 3.4 3.3 3.0

P/CF

- 15.6 17.7 17.9 18.9 - 19.8 18.5 19.2 17.8 - 19.2 18.3 16.5 12.0

ROE %

32.87 19.68 51.11 6.02 23.25 - 25.42 25.60 23.49 21.66 - 23.40 18.68 16.94 23.57

ROA %

13.46 7.81 20.98 2.45 8.41 - 9.59 10.00 11.71 11.55 - 12.45 10.42 8.51 12.96

ROCE %

- - - - - - 14.23 14.79 17.23 18.17 - 19.39 14.46 13.61 21.23

Current Ratio

1.7 1.7 1.7 1.7 1.6 - 1.3 1.5 2.5 2.2 - 2.4 2.2 2.4 2.1

DSO

62.0 61.1 64.6 263.4 30.0 - 64.4 63.1 59.4 55.9 - 53.9 60.0 59.4 57.9

DIO

160.7 156.9 148.2 153.9 60.0 - 119.9 116.3 137.4 137.0 - 131.3 132.8 113.2 104.5

DPO

134.5 132.5 142.2 160.3 61.0 - 113.6 101.9 116.7 113.4 - 122.5 105.6 103.1 109.2

Operating Cycle

222.7 218.0 212.9 417.3 90.0 - 184.3 179.4 196.8 192.9 - 185.3 192.7 172.5 162.4

Cash Conversion Cycle

88.2 85.5 70.7 256.9 29.0 - 70.7 77.4 80.1 79.5 - 62.8 87.1 69.5 53.2

All numbers in USD currency

Quarterly Financial Ratios Johnson & Johnson

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

2.14 2.3 4.57 1.12 1.95 1.35 10.32 1.98 -0.03 - 1.7 1.83 1.96 - 1.39 2.38 2.35 - 1.35 1.38 2.2 1.52 0.67 2.11 1.41 1.14 1.47 1.47 1.63 -3.99 1.4 1.42 1.63 1.16 1.56 1.46 1.62 - 1.21 1.63 1.55 0.9 1.69 1.53 1.67 1.25 1.06 1.36 1.25 0.93 1.08 0.51 1.43 0.71 1.17 1.01 1.27

EBITDA per Share

- - - - - - - - - - 0.38 0.42 0.67 - 2.11 0.46 0.72 - 2.01 1.32 0.66 - 1.97 1.31 0.66 - 1.94 1.29 0.65 - 1.41 0.77 0.34 - 0.99 0.65 0.32 - 0.98 0.64 2.42 - 3.54 2.77 2.36 - 2.44 2.51 1.98 - 2.34 1.56 2.16 - 2.54 1.85 2

ROE %

31.48 31.53 29.12 51.58 54.47 47.83 49.15 18.59 18.16 19.17 24.39 23.63 26.35 23.65 29.17 29.46 26.20 20.73 27.47 24.90 28.57 25.42 23.77 27.41 24.60 25.60 2.70 2.38 2.12 2.16 24.49 24.10 23.25 22.04 22.21 21.04 21.87 17.41 21.02 23.14 22.99 23.40 24.54 21.76 20.73 18.68 17.88 18.44 15.43 16.74 16.21 16.84 19.14 18.91 5.20 4.47 5.81

ROA %

12.73 12.64 11.67 21.67 22.84 20.22 20.87 7.74 7.94 8.32 10.37 6.98 10.54 9.20 11.28 11.31 10.04 8.11 10.65 9.68 10.95 9.59 9.03 10.49 9.52 10.00 1.20 1.02 0.87 0.83 10.05 10.70 11.12 11.58 11.69 11.17 11.73 9.30 11.23 12.34 12.21 12.46 13.18 11.80 11.39 10.42 9.89 10.09 8.36 8.94 8.72 9.13 10.45 10.44 2.86 2.48 3.21

ROCE %

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 8.58 17.17 27.28 28.81 37.23 26.64 31.86 26.98 25.34 18.06 23.96 24.63 21.95 17.91 25.47 27.12 28.72 21.15 7.56 5.69 7.89

Current Ratio

1.7 1.7 1.7 1.6 1.6 1.7 1.8 1.7 1.6 1.7 1.7 - 1.7 1.6 1.6 1.6 1.6 - 1.6 1.7 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 2.1 2.1 2.1 2.1 - 2.2 2.2 2.1 2.1 2.1 2.1 2.1 2.3 2.3 2.3 2.3 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2

DSO

67.4 65.1 67.1 64.9 62.5 63.5 67.5 70.2 71.0 - 36.3 29.6 56.8 - 58.2 58.3 30.5 - 63.2 73.5 64.7 63.7 63.8 64.3 65.1 63.1 63.2 61.8 62.9 61.0 62.6 65.3 62.2 - - - - - - - - - 54.3 51.4 57.2 - 60.8 59.8 60.0 - 60.5 62.6 - - - - -

DIO

172.2 155.9 156.7 162.3 156.4 158.2 166.3 181.4 172.6 - 86.3 63.3 122.1 - 128.9 120.6 64.3 - 124.5 126.8 115.6 - 119.9 118.6 121.5 - 119.1 113.3 119.8 - 115.5 - - - - - - - - - - - - - - - - - - - - - - - - - -

DPO

119.3 113.7 114.7 116.7 113.1 115.8 129.8 143.7 147.5 - 75.0 53.6 113.0 - 111.2 103.5 54.9 - 90.4 98.3 103.1 - 113.5 112.3 110.9 - 104.4 99.3 102.4 - 96.3 - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

239.6 221.0 223.8 227.2 218.9 221.7 233.8 251.7 243.6 - 122.6 92.9 178.9 - 187.2 178.9 94.8 - 187.7 200.3 180.3 63.7 183.6 182.9 186.7 63.1 182.3 175.0 182.7 61.0 178.1 65.3 62.2 - - - - - - - - - 54.3 51.4 57.2 - 60.8 59.8 60.0 - 60.5 62.6 - - - - -

Cash Conversion Cycle

120.3 107.3 109.0 110.6 105.9 105.9 104.0 108.0 96.1 - 47.5 39.3 65.9 - 76.0 75.4 39.9 - 97.4 102.0 77.2 63.7 70.1 70.5 75.7 63.1 77.9 75.8 80.3 61.0 81.8 65.3 62.2 - - - - - - - - - 54.3 51.4 57.2 - 60.8 59.8 60.0 - 60.5 62.6 - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Johnson & Johnson, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.22 -2.32 % $ 2.55 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.82 -3.48 % $ 4.47 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 164.71 -1.01 % $ 8.19 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.73 -2.49 % $ 1.11 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
$ 8.5 -2.63 % $ 1.39 B britainBritain
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 23.88 - $ 2.92 B usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 18.08 1.06 % $ 868 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Certara Certara
CERT
$ 7.19 1.93 % $ 1.15 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 17.72 -2.37 % $ 454 M usaUSA
Exelixis Exelixis
EXEL
$ 40.99 -0.1 % $ 11.1 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Galapagos NV Galapagos NV
GLPG
$ 33.13 -2.82 % $ 2.69 B belgiumBelgium
Greenwich LifeSciences Greenwich LifeSciences
GLSI
$ 27.7 1.12 % $ 361 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 27.67 -6.69 % $ 17.7 B danmarkDanmark
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 26.04 -3.07 % $ 697 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
$ 0.99 -2.92 % $ 72.7 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 69.39 -0.67 % $ 8.32 B usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 28.56 -1.19 % $ 1.64 B usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 6.3 -3.67 % $ 51.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Immuron Limited Immuron Limited
IMRN
$ 0.75 -0.69 % $ 6.43 M australiaAustralia
Immatics N.V. Immatics N.V.
IMTX
$ 9.86 -1.3 % $ 620 M germanyGermany
Immunic Immunic
IMUX
$ 1.1 3.3 % $ 171 M usaUSA
Immunovant Immunovant
IMVT
$ 26.99 -2.74 % $ 4.09 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Inhibrx Inhibrx
INBX
$ 75.96 -1.97 % $ 3.58 B usaUSA
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 0.75 -8.49 % $ 1.84 M canadaCanada
INmune Bio INmune Bio
INMB
$ 1.41 6.07 % $ 25.4 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 146.89 0.39 % $ 29.2 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
$ 3.19 -4.49 % $ 1.14 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.63 -1.21 % $ 235 M franceFrance
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 29.11 -0.31 % $ 1.69 B usaUSA